Find a trial

Our clinical trials database will help you look for a clinical trial that might be suitable for you. We hope this helps you to make informed decisions and choices about your lymphoma treatment and care. 

Questions about Lymphoma TrialsLink and how to use it? Read more about Lymphoma TrialsLink here or if you have a general question about clinical trials in the UK or Lymphoma TrialsLink, please contact us at trialslink@lymphoma-action.org.uk.

Note: We are not able to refer people to specific trials. If you’re interested in taking part in a trial you have found on Lymphoma TrialsLink, we recommend that you print the trial summary and discuss it with your consultant. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.

Trial name Closing date Status

ME-401-003: a phase 2 study of a new drug called ME-401 in people with relapsed or refractory follicular lymphoma

Open

PROCLIPI: a study aiming to identify factors important in predicting the outcome of cutaneous (skin) lymphomas, mycosis fungoides and Sezary syndrome

Open

JCAR017-BCM-001: a phase 2 trial of JCAR017 CAR T-cell therapy in adults with relapsed or refractory high-grade B-cell non-Hodgkin lymphoma

Open

GO29781: a phase 1/1b trial testing mosunetuzumab, on its own or with atezolizumab, in people with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia (CLL) that has come back or has not responded to treatment

Open

RESMAIN: a phase 2 trial testing resminostat as a maintenance treatment for people with advanced stage mycosis fungoides (MF) or Sézary syndrome (SS)

Open

RiVa: a phase 2 trial testing the combination of rituximab and varlilumab for people with relapsed or refractory B-cell non-Hodgkin lymphoma

Open

LYMRIT-37-07: a phase 1b trial of Betalutin® and rituximab in people with relapsed or refractory follicular lymphoma

Open

AZD6738: a phase 1/2 trial testing ceralasertib alone or in combination with acalabrutinib for people with chronic lymphocytic leukaemia (CLL) who have had previous treatment

Open

MaPLe: a study looking at the genes in follicular and diffuse large B cell lymphomas

Open

TELLOMAK: a phase 2 study of a new treatment called IPH4102 in relapsed or refractory T-cell lymphomas

Open

ALPINE: a phase 3 trial of zanubrutinib in people with relapsed or refractory chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL)

Open

Cardiac CARE: a phase 2 trial to find out if angiotensin receptor blockers and beta blockers can prevent heart damage in people having chemotherapy for non-Hodgkin lymphoma

Open

AZD4573: a phase 1 trial looking at a new treatment for people with relapsed or refractory lymphoma and other blood cancers

Open

AVENuE: a phase 2 trial of avelumab for untreated advanced classical Hodgkin lymphoma

Open

STARTRK-2: a phase 2 trial testing a newer drug, entrectinib, in people with solid tumours, including anaplastic large cell lymphoma

Open

BGB-3111-212: a randomised phase 2 trial to see if adding zanubrutinib (BGB-3111) to obinutuzumab can improve outcomes for people with follicular lymphoma who have had previous treatment

Open

PRISM: a phase 1 study testing acalabrutinib in combination with AZD9150 or AZD6738 in people with high-grade non-Hodgkin lymphoma that has come back or has not responded to treatment

Open

Hu5F9-G4: a phase 1/2 trial testing a new drug, Hu5F9-G4, with rituximab for people with relapsed or refractory non-Hodgkin lymphoma

Open

BONES: The British Osteonecrosis Study to look at the development of osteonecrosis (a bone problem) in children and young people with acute lymphoblastic leukaemia and lymphoblastic lymphoma

Open

ENRICH: a phase 2/3 trial looking at first-line treatment options for people over 60 with mantle cell lymphoma who are unable to have a stem cell transplant

Open

PARADIGME: a phase 2 trial comparing two different doses of Betalutin and lilotomab in people with relapsed or refractory follicular lymphoma

Open

NP39488: a phase 1 trial testing atezolizumab and a new treatment called RO7082859 in people with B-cell non-Hodgkin lymphoma that has come back or has not responded to treatment

Open

FLAIR: a randomised phase 3 trial comparing treatments containing ibrutinib with standard first treatment for chronic lymphocytic leukaemia (CLL)

Open

NF-kB in CLL: a study looking at a signalling pathway in blood samples of people with chronic lymphocytic leukaemia (CLL)

Open

B-MIND: a phase 2/3 trial testing bendamustine and a new antibody drug MOR208 against bendamustine and rituximab in people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

Open

KEYNOTE 051: a phase 1 / 2 trial aiming to test pembrolizumab in children with a solid tumour (including lymphoma) that has come back or is difficult to treat

Open

PembroWM: a phase 2 trial of rituximab and pembrolizumab in people with relapsed or refractory Waldenström’s macroglobulinaemia

Open

Delphinus: a phase 2 study of the antibody daratumumab in children and young adults (1–30 years old) with relapsed or refractory B-cell or T-cell lymphoblastic lymphoma

Open

LYM1: a study to collect and test samples from different types of lymphoma and try to better understand how lymphomas develop and respond to treatment

Open

BI-1206: a phase 1/2 trial testing a new antibody treatment for people with CLL or another B-cell lymphoma

Open

ORACLE: a phase 3 trial of azacitidine for people with relapsed or refractory angioimmunoblastic T-cell lymphoma (AITL), follicular T-cell lymphoma (FTCL) or peripheral T-cell lymphoma with T-follicular helper phenotype

Open

CheckMate 744: phase 2 trial testing nivolumab with brentuximab vedotin for children and young adults with relapsed or refractory classical Hodgkin lymphoma

Open

ALEXANDER: a phase 1/2 trial testing AUTO3 CAR-T cells with pembrolizumab consolidation as treatment for people with diffuse large B-cell lymphoma (DLBCL) that has relapsed (come back) or was refractory (didn’t respond) to previous treatment

Open, Results

SPARKLE: a phase 3 trial of ibrutinib for children and young adults (first diagnosed when under 18) with relapsed or refractory mature B-cell non-Hodgkin lymphoma

Open

GEN3013: a phase 1/2 trial of GEN3013 in people with B-cell non-Hodgkin lymphoma that has come back or has not responded to treatment

Open

TREATT: a phase 3 trial testing tranexamic acid to reduce bleeding after chemotherapy

Open

UNITY NHL: a randomised phase 2 trial testing new treatments for people with relapsed or refractory non-Hodgkin lymphoma

Open

iPOLYMATH: a study to find out more about how B cells become cancerous and how the conditions the cells live in may contribute to that process

Open

AUTO4 in T-cell lymphoma: a phase 1/2 trial testing AUTO4 CAR-T cells as treatment for people with T-cell lymphoma that has relapsed (come back) or was refractory (didn’t respond) to previous treatment

Open

EuroNet-PHL-C2: a phase 3 treatment study for children and young people (under 25) with classical Hodgkin lymphoma

Open

ANIMATE: a phase 2 study of nivolumab for relapsed or refractory classical Hodgkin lymphoma

Open

CCS1477-02: a phase 1/2a study of CCS1477 in blood cancers, including relapsed or refractory non-Hodgkin lymphoma

Open

ToTem: a phase 1 trial of donor ‘effector memory’ T cells to improve immune system recovery after donor (allogeneic) stem cell transplants

Open

PERSPECTIVE: a randomised phase 3 trial testing whether adding ibrutinib to rituximab can improve outcomes for older people with untreated follicular lymphoma

Open

OxPLoreD: a study to find out more about pre-cancerous blood conditions

Open

PORT: a phase 2 trial testing pembrolizumab and radiotherapy in people with relapsed or refractory T-cell skin lymphoma

Open

BOOST: studying samples from stem cell transplant donors and recipients to improve transplant success rates and reduce side effects

Open

STELLAR: a phase 2 trial of acalabrutinib in people with Richter syndrome

Open

BGB-3111-304: a randomised phase 3 trial comparing zanubrutinib with a standard treatment for people with untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL)

Open

PETReA: a phase 3 trial testing whether PET scans can help make treatment decisions for people with follicular lymphoma

Open

S65487: a phase 1 trial of a targeted drug called S65487 in people with non-Hodgkin lymphoma and other blood cancers that have come back or not responded to treatment

Open

NP40126: a phase 1 trial testing a new drug given with chemo-immunotherapy for people with relapsed or refractory follicular lymphoma or untreated diffuse large B-cell lymphoma (DLBCL)

Open

ARGO: a phase 2, randomised trial testing a new drug in combination with standard treatment for people with relapsed or refractory DLBCL

Open

Mature lymphoid malignancies observational study: a study looking at the cells in lymphoma

Open

HOVON 127: a phase 3 trial comparing two treatment regimens for untreated high-risk Burkitt lymphoma

Open

ECHELON-2: a phase 3 trial comparing brentuximab vedotin and CHP chemotherapy with standard CHOP in people with T-cell lymphoma that has not yet been treated

Results

CHEMO-T: a phase 2 trial comparing 2 different chemotherapy regimens in people with T-cell lymphoma who have not yet been treated

Results

LEGEND: a phase 2 trial to find out if adding lenalidomide to chemo-immunotherapy is as effective as a standard regimen for people with relapsed or refractory diffuse large B-cell lymphoma

Results

Inter-B-NHL Ritux 2010: a phase 3 trial to find out if adding rituximab to chemotherapy improves outcomes for people under 18 with advanced-stage B-cell non-Hodgkin lymphoma or B-cell leukaemia

Results

CLARITY: a phase 2 trial using venetoclax and ibrutinib for chronic lymphocytic leukaemia that has come back or is not responding to treatment

Results

L-MIND: a phase 2 trial testing lenalidomide and a new antibody drug MOR00208 in people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

Results

G100 and pembrolizumab: a phase 1/2 trial testing newer drugs for people with follicular lymphoma and marginal zone lymphoma

Results

LYMRIT-37-01: a phase 1 / 2 trial of a new drug, Betalutin, in non-Hodgkin lymphoma that has come back

Results

KEYNOTE-204: a phase 3 trial comparing pembrolizumab with brentuximab vedotin in people with relapsed or refractory classical Hodgkin lymphoma

Results

HORIZONS: a study of the impact of a cancer diagnosis and treatment on everyday life in people with diffuse large B-cell lymphoma (DLBCL) and other cancers

Results

G029365: a phase 1/2 trial of polatuzumab vedotin, bendamustine and rituximab in people with diffuse large B-cell lymphoma that has come back (relapsed) or not responded (refractory) to treatment

Results

ALEXANDER: a phase 1/2 trial testing AUTO3 CAR-T cells with pembrolizumab consolidation as treatment for people with diffuse large B-cell lymphoma (DLBCL) that has relapsed (come back) or was refractory (didn’t respond) to previous treatment

Open, Results

Isatin sulfonamide in PET-CT scans: a pilot study using isatin sulfonamide to improve PET-CT scans in lymphoma

Closed

TORCH: a phase 2 trial of a targeted drug, vistusertib, with and without rituximab in people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

Closed

Brentuximab vedotin in DLBCL: a phase 2 trial testing a treatment regimen for people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) or grade 3b follicular lymphoma

Closed

BiLD: finding new ways to measure how well chemotherapy works in lymphoma

Closed

IcICLLe Extension Study: a phase 2 trial testing ibrutinib and obinutuzumab for people with relapsed or refractory chronic lymphocytic leukaemia (CLL)

Closed

Lactate Imaging: a study to see if measuring lactate levels in cancers can help to show if treatment is working

Closed

Masitinib in PTCL: a phase 2 / 3 trial looking at masitinib alone and with chemotherapy in people whose peripheral T cell lymphoma has come back or not responded to treatment

Closed

Targeted radiotherapy for SCT: a phase 1 / 2 trial to see if radiotherapy to the bone marrow is safe before an allogeneic stem cell transplant and whether it can improve its success

Closed

M7583: a phase 1 / 2 trial testing a new lymphoma drug for B-cell non-Hodgkin lymphoma

Closed

UNITY CLL: a randomised phase 3 trial comparing new treatments with obinutuzumab and chlorambucil for people with untreated or previously treated chronic lymphocytic leukaemia (CLL)

Closed

ICEPOP: a study looking at features of diffuse large B-cell lymphoma (DLBCL) linked to the Epstein-Barr virus (EBV)

Closed

ELEVATE CLL R/R: a randomised phase 3 trial comparing acalabrutinib with ibrutinib for people with relapsed or refractory high-risk chronic lymphocytic leukaemia (CLL)

Closed

CALiBRe: a phase 2 trial to investigate how idelalisib works in people with relapsed or refractory chronic lymphocytic leukaemia (CLL) who can’t have ibrutinib or didn’t respond to ibrutinib

Closed

RIAltO: a phase 3 trial to see how well ofatumumab works with chemotherapy for people with chronic lymphocytic leukaemia who can't have more intensive treatment

Closed

CITADEL-202: a phase 2 trial testing a new drug, INCB050465, for people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

Closed

TAK-659: a phase 1 trial testing a new drug called TAK-659 for people with non-Hodgkin lymphoma that has come back or not responded to treatment

Closed

JAVELIN HL: a phase 1 trial to find the best dose of avelumab for people with relapsed or refractory advanced-stage classical Hodgkin lymphoma

Closed

Tirabrutinib in B-cell lymphoma: a phase 1 study looking at a new treatment called tirabrutinib for people with B-cell lymphoma that has come back or not responded to treatment

Closed

ADCT-402: a phase 1 study testing a new drug called ADCT-402 for people with B-cell non-Hodgkin lymphoma that has come back or has not responded to treatment

Closed

BGB-3111 in WM: a phase 3 trial comparing ibrutinib and BGB-3111 for people with Waldenström’s macroglobulinemia (WM)

Closed

Blinatumomab consolidation: a phase 2 trial testing a new antibody drug after chemotherapy for people with newly diagnosed high-risk diffuse large B-cell lymphoma

Closed

BACH: collecting research samples from people with Hodgkin lymphoma to develop a test that shows how well treatment is working

Closed

PIX-R: a phase 3 trial to see how well pixantrone works for people with relapsed or refractory diffuse large B cell lymphoma or grade 3 (fast growing) follicular lymphoma

Closed

VENICE-I: a phase 3 trial testing venetoclax for people with relapsed or refractory chronic lymphocytic leukaemia

Closed

Acalabrutinib in CLL: a phase 3 trial comparing acalabrutinib with other treatments for people with relapsed or refractory chronic lymphocytic leukaemia (CLL)

Closed

IELSG 42: a phase 2 trial testing the MARIETTA regimen in people with untreated or relapsed DLBCL involving their central nervous system

Closed

Ibrutinib, lenalidomide and rituximab in DLBCL: a phase 1/2 trial testing a combination of newer drugs for people with relapsed or refractory non-GCB subtype diffuse large B-cell lymphoma

Closed

CLARITY tissue collection: collecting research samples from people with CLL or mantle cell lymphoma who are having treatment with ibrutinib

Closed

ADCT-301: a phase 1 study testing a new drug, ADCT-301, for people whose Hodgkin or non-Hodgkin lymphoma has come back or has not responded to treatment

Closed

EuroNet PHL-LP1: a phase 3 treatment study for children and young people with nodular lymphocyte-predominant Hodgkin lymphoma

Closed

UK Haplo: a phase 2 study looking at the safety and effectiveness of allogeneic (donor) stem cell transplants using a partially matched donor in people with lymphoma and other blood cancers

Closed

ProT4: a phase 2 trial to test whether giving donor lymphocytes can help prevent lymphoma relapsing after a sibling donor stem cell transplant

Closed

CITADEL: a phase 2 trial to find out if T-cells that target EBV can be used to treat EBV-positive extranodal NK/T-cell lymphoma

Closed

UKALL 2011: a phase 3 trial looking at reducing side effects by changing the standard treatment for acute lymphoblastic leukaemia or lymphoblastic lymphoma in children and young people aged 1-24

Closed

Tazemetostat: a phase 1 / 2 trial testing a new lymphoma drug for B-cell lymphoma

Closed

PQR309: a phase 2 trial testing a targeted drug, PQR309, in people with relapsed or refractory systemic (whole-body) lymphoma

Closed

RAMO-2: a randomised, phase 3 trial comparing original rituximab with the biosimilar rituximab SAIT101 in people with untreated follicular lymphoma

Closed

INCA: a phase 2 trial testing inotuzumab ozogamicin and gemcitabine with chemo-immunotherapy for people with diffuse large B-cell lymphoma (DLBCL) who have not yet been treated and can’t have standard treatment

Closed

BAY 1862864: a phase 1 study testing a new treatment called ‘BAY 1862864’ for people with non-Hodgkin lymphoma that has come back or has not responded to treatment

Closed

TIER: a phase 2 trial of the TIER regimen of chemotherapy and rituximab antibody therapy in people with relapsed or refractory primary central nervous system lymphoma

Closed

GLOW: a phase 3 trial testing ibrutinib and venetoclax for people with untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL)

Closed

Idelalisib in follicular lymphoma: a phase 3 trial comparing 2 different doses of idelalisib for follicular lymphoma that has come back or has not responded to treatment

Closed

GSK2857916: a phase 1 trial testing a new drug for people with non-Hodgkin lymphoma or myeloma that has come back or not responded to treatment

Closed

SYMPATICO: a phase 3 trial testing ibrutinib with venetoclax for people with mantle cell lymphoma that has come back or didn’t respond to treatment

Closed

NHL in young adults: a population study of people aged 15–29 with non-Hodgkin lymphoma

Closed

TAK-659 in DLBCL: a phase 2 trial testing an investigational drug for people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

Closed

SADAL: a phase 2 trial testing a new targeted drug called selinexor for people with relapsed or refractory diffuse large B-cell lymphoma

Closed

CheckMate 436: a phase 1/2 trial testing nivolumab with brentuximab vedotin for people with relapsed or refractory non-Hodgkin lymphoma

Closed

RomiCar: a phase 1/2 trial to find the best dose and test the effectiveness of 2 newer drugs - romidepsin and carfilzomib - in people with relapsed or refractory peripheral T-cell lymphoma

Closed

AZD3965: a phase 1 trial looking at a new treatment called AZD3965 for people with relapsed or refractory lymphoma and for other cancers

Closed

ZUMA-7: a phase 3 trial comparing the CAR T-cell treatment axicabtagene ciloleucel with high-dose chemotherapy and self (autologous) stem cell transplant for people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

Closed

COSMOS: a phase 2 trial testing idelalisib and a new antibody drug MOR00208 in people with relapsed and refractory chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL)

Closed

MCL Biobank: collecting samples from people with untreated mantle cell lymphoma for research

Closed

EBV in NK/T-cell cancers: a study to find out more about the links between the Epstein-Barr virus (EBV) and NK/T-cell cancer

Closed

COBALT: a phase 1 trial testing CD19 CAR-T cells as treatment for people with diffuse large B-cell lymphoma (DLBCL) that has relapsed (come back) or was refractory (didn’t respond) to previous treatment

Closed

PROCLAIM-CX-072: a phase 1/2 trial to find the best dose and test the effectiveness of a newer drug, CX-072, in people with solid tumours or lymphoma

Closed

ACE-LY-110: a phase 1/2 trial testing the combination of newer drugs acalabrutinib and vistusertib for people with diffuse large B-cell lymphoma (DLBCL)

Closed

POLARIX: a randomised phase 3 trial comparing polatuzumab vedotin and vincristine, when given in combination with chemotherapy and antibody therapy for people with untreated diffuse large B-cell lymphoma (DLBCL)

Closed

AZTEC: phase 2 trial of azacitidine for people with chronic graft versus host disease (GvHD) after an allogeneic stem cell transplant

Closed

Brentuximab in DLBCL and grade 3b follicular lymphoma: a phase 2 trial to see if adding brentuximab to rituximab and bendamustine can improve outcomes for people whose lymphoma has not responded well to treatment

Closed

OASIS: a phase 1/2 trial testing the targeted drugs obinutuzumab, ibrutinib and venetoclax (ABT-199) for people with relapsed or refractory mantle cell lymphoma

Closed

GSK525762: a phase 1/2 trial to find the best dose and test the effectiveness of a new targeted drug in people with relapsed or refractory lymphoma or other blood cancers

Closed

REBEL: a phase 2 trial to see how well lenalidomide and rituximab work with or without bendamustine in people with relapsed follicular lymphoma

Closed

AVAIL-T: a phase 2 trial testing a new drug, avelumab, in people with relapsed or refractory peripheral T-cell lymphoma (PTCL)

Closed

ACCEPT: a phase 1/2 trial testing whether adding acalabrutinib to R-CHOP can improve outcomes for people with diffuse large B-cell lymphoma (DLBCL)

Closed

Loncastuximab tesirine in DLBCL: a phase 2 trial testing a new drug, in people with relapsed or refractory diffuse large B-cell lymphoma or other large B-cell lymphomas

Closed

CITADEL-204: a phase 2 trial testing INCB050465 for people with marginal zone lymphoma who have had previous treatment

Closed

UCB-SCT: a phase 3 trial of allogeneic (donor) stem cell transplantation using umbilical cord blood in people with lymphoma that has come back or has not responded to treatment

Closed

MAGNOLIA: a phase 2 open-label study of zanubrutinib in people with relapsed or refractory marginal zone lymphoma

Closed

Hodgkin lymphoma survivorship questionnaire: a study to find out the long-term side effects of treatment for Hodgkin lymphoma in young women

Closed

CHRONOS-4: a randomised phase 3 trial testing the targeted treatment copanlisib in combination with rituximab and chemotherapy for people with relapsed or refractory low-grade non-Hodgkin lymphoma

Closed

IELSG 37: a phase 3 trial to find out if radiotherapy can be safely omitted in people with primary mediastinal large B-cell lymphoma who are PET negative after chemotherapy

Closed

BMPD: using blood tests to stage lymphoma

Closed

PTCL Biobank: collecting samples from people with T-cell lymphoma for research

Closed

SOLAR: a randomised phase 2 study of cobomarsen in people with mycosis fungoides

Closed

CITADEL-205: a phase 2 trial testing INCB050465 for people with mantle cell lymphoma who have had previous treatment

Closed

Betalutin: a phase 1 study to find the best dose of a new treatment called betalutin for people with diffuse large B-cell lymphoma that has come back or not responded to treatment

Closed

TIDaL: a phase 2 trial of ibrutinib with rituximab for people with post-transplant lymphoproliferative disorder

Closed

CXD101: a phase 1 trial looking at a new treatment called CXD101 for people with relapsed or refractory lymphoma and for other cancers

Closed

ASTX660: a phase 1/2 trial to find the best dose and test the effectiveness of a new targeted drug in people with solid tumours or lymphoma

Closed

Blinatumomab in high-grade non-Hodgkin lymphoma: phase 2/3 trial testing a new antibody drug for people with relapsed or refractory high-grade B-cell non-Hodgkin lymphoma (NHL)

Closed

JAVELIN DLBCL: a phase 1/3 trial testing a new drug, avelumab, in people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

Closed

ICAT: a phase 2 trial to see if specially treated T cells can help the immune system to recover after a stem cell transplant for lymphoma

Closed

FUSION NHL001: a phase 1 / 2 trial aiming to find the maximum safe dose and the possible side effects of a drug called durvalumab for B cell lymphoma or chronic lymphocytic leukaemia (CLL) that has come back or is difficult to treat

Closed